SAB Biotherapeutics (SABS) Notes Payables (2020 - 2025)
Historic Notes Payables for SAB Biotherapeutics (SABS) over the last 6 years, with Q1 2025 value amounting to $138554.0.
- SAB Biotherapeutics' Notes Payables fell 8341.6% to $138554.0 in Q1 2025 from the same period last year, while for Mar 2025 it was $138554.0, marking a year-over-year decrease of 8341.6%. This contributed to the annual value of $275849.0 for FY2024, which is 7374.99% down from last year.
- As of Q1 2025, SAB Biotherapeutics' Notes Payables stood at $138554.0, which was down 8341.6% from $275849.0 recorded in Q4 2024.
- In the past 5 years, SAB Biotherapeutics' Notes Payables registered a high of $1.8 million during Q4 2021, and its lowest value of $25013.0 during Q3 2022.
- In the last 5 years, SAB Biotherapeutics' Notes Payables had a median value of $541644.0 in 2023 and averaged $609781.8.
- Its Notes Payables has fluctuated over the past 5 years, first soared by 206545.0% in 2023, then plummeted by 8341.6% in 2025.
- Over the past 5 years, SAB Biotherapeutics' Notes Payables (Quarter) stood at $1.8 million in 2021, then crashed by 57.0% to $772665.0 in 2022, then soared by 36.0% to $1.1 million in 2023, then tumbled by 73.75% to $275849.0 in 2024, then tumbled by 49.77% to $138554.0 in 2025.
- Its Notes Payables was $138554.0 in Q1 2025, compared to $275849.0 in Q4 2024 and $615818.0 in Q2 2024.